I am joined by the amazing Dr. Paul Richardson from the Dana-Farber Cancer Institute to discuss the SUCCESSOR trial that was presented at EHA. This trial discusses CELMoDs by highlighting a landmark randomized Phase 3 clinical study evaluating the oral medication mezigdomide combined with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma. Results show the regimen significantly improves progression-free survival.

Dr. Richardson puts this data into perspective. A must-watch on YouTube and listen here

Dr. Bruna Pellini of Baptist Health Miami Cancer Institute joins Healthcare Unfiltered EXPRESS to break down the most important lung cancer data presented at ASCO 2026. Together, we discuss the trials most likely to influence clinical practice, what they mean for patients today, and how they may reshape future treatment decisions. Watch on YouTube, subscribe, share, review, and join the conversation.

Hot off the press, the ENDURANCE trial was JUST published in NEJM. This trial explored whether patients with newly diagnosed myeloma benefit from long-term maintenance lenalidomide versus 2-years only. Dr. Vincent Rajkumar, senior author on the paper, shares the findings and context. Please subscribe, share, and join the conversation.

Dr. Amer Zeidan joins the Healthcare Unfiltered EXPRESS to discuss the recently published KOMET-007 trial, which made its way to print in Blood. Dr. Zeidan discusses how Menin inhibitors are transforming how we approach AML like no other therapies before. What does the future hold and how will the results of this trial affect therapy? The KOMET-007 trial is a Phase 1/2 clinical study evaluating the targeted Menin inhibitor ziftomenib in combination with standard-of-care chemotherapies for acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements.

A must listen - please share subscribe, and join the conversation.

On this Healthcare Unfiltered EXPRESS, Dr. Arturo Bonilla, CMO of Massive Bio and an AI oncologist expert who leads many AI efforts nationally, joined Chadi to provide his insights on where AI is being applied in patient care. He gives timely use case examples that will resonate with everyone.

AI is here to stay and we must know where and how it applies.

Please join the conversation, subscribe, like, comment, and write a review.

Dr. Virginia Kaklamani joins Healthcare Unfiltered EXPRESS to discuss the recent FDA-approved indications for T-DXd in breast cancer, and what this means for treating patients with the disease. A critical episode ahead of the annual ASCO meeting. Check it out, subscribe, rate, review, and join the conversation.

Dr. Rani Bansal of Duke University joins the show to share her insights on the latest ESMO Breast meeting that concluded in Berlin. Dr. Rani shares data on the top 5 abstracts that may change or inform practice.

Check it out, share, subscribe, and join the conversation.

Dr. Emily Landon of the University of Chicago joins the show to explain everything you must know about the Hantavirus - should we be concerned? What to do? What not to do? Is this another COVID?
Get the facts right here, and please share, subscribe, and join the conversation.